Future therapies for schizophrenia

Bibliography

• FRANGOU S, MURRAY RM: Schizophrenia. Dunitz M, London, (1996). An overview of diagnosis, possible aetiologies and treatments of schizophrenia in an introductory textbook.
   Google Scholar
• MURRAY RM: Neurodevelopmental schizophrenia - the rediscovery of dementia-praecox. Br. J. Psychiatry (1994) 165:6–12.
   Web of Science ®Google Scholar
• DELAY J, DENIKER 0: Characteristiques psychophysi-ologiques des medicaments neuroleptiques. In: The PF-chotropic Drugs. Garattini J & Ghetti V. (Eds.), Elsevier, Amsterdam (1957) 485–501.
   Google Scholar
• GERLACH J: New antipsychotics: classification, efficacy and adverse effects. Schizophr. Bull. (1991) 17:289–309.
   PubMed Web of Science ®Google Scholar
• KANE J, HONIGFIELD G, SINGER J, MELTZER H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psy-chiatry (1988) 45:789–796.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, BASTANI B, KWON KY et al.: A prospective study of clozapine in treatment-resistant schizophrenic patients. Preliminary report. Psychopharmacology (1989) 99:S68–S72.
   Google Scholar
• LIEBERMAN JA: Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br. J. Psychiatry (1993) 163 (Suppl. 22):7–18.
   Google Scholar
• PICKAR D: Prospects for pharmacotherapy of schizo-▪phrenia. Lancet (1995) 345:557–562.
   PubMed Web of Science ®Google Scholar
• MELTZER HY: An overview of the mechanism of action of clozapine. j Clin. Psychiatry (1994) 55 (Suppl. B):47–52.
   Google Scholar
• BOULTON et al.: Animal models for assessing anxiolytic, neuroleptic and antidepressant drug action. In: Neuromethods, Analysis of Psychiatric Drugs. Humana Press, New Jersey, (1988) 10:379–427.
   Google Scholar
• JANSSEN PAJ, NIEMEGEERS CJE, AWONTERS F etal: Phar-macology of risperidone (R64 766) a new antipsychotic with serotonin S2 and dopamine D2 antagonist proper-ties. J. Pharamacol. Exp. 7her. (1988) 244:685–693.
   Google Scholar
• HEINRICH K, KLIESER E, LEHMANN E, KINZLER E, HRUSCHKA H: Risperidone versus clozapine in the treatment of schizophrenic patients with acute symp-toms: a double-blind, randomised trial. Prog Neuropsy-chopharmacol Biol. Pychiatly (1994) 18:129–37.
   PubMed Web of Science ®Google Scholar
• CLAUS A, BO LLEN J, DE CUYPER eta].: Risperidone versus haloperidol inthe treatment of chronic schizophrenic in-patients: a multi centre double-blind comparative study. Acta Psychiatr. Scan. (1992) 85:295–305.
   Google Scholar
• BORISON RL, PATHIRAJA AP, DIAMOND BI, MEIBACH RC: Risperidone in the treatment of schizophrenia. Psycho-pharmacol Bull. (1992) 28:213–218.
   PubMed Web of Science ®Google Scholar
• MARDER SR, MEIBACH RC: Risperidone in the treatment of schizophrenia. Am. J. Psychiatry (1994) 151:825–835.
   PubMed Web of Science ®Google Scholar
• MULLER-SPAHN F: Risperidone in the treatment of chronic schizophrenic patients: and international dou-ble-blind parallel group study versus haloperidol. Neuropharmacol (1992) 15 (Suppl. 1):90A–91A.
   Google Scholar
• CESKOVA E, SVESTKA J: Double-blind comparison of risperidone and haloper idol in schizop hre nia and schi-zoaffective psychoses. PharmacopFchiatry (1993) 26:121–124.
   PubMed Web of Science ®Google Scholar
• CHOUINARD G, JONES B, REMINGTON G eta].: A Cana-dian multi-center placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychophar-macol. (1993) 13(1):25–40.
   Google Scholar
• BORISON RL: Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. j Clin. Psy-chopharmacol (1995) 15 (Suppl. 0:245295.
   Google Scholar
• FULLER RW, SNODDY HD: Neuro endocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candi-date. Res. Commun. Chem. Pathol. Pharmacol. (1992) 77(1)87–93.
   Google Scholar
• GOLDSTEIN JM, LITWIN LC, SUTTON EB, MALICK JB: Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacol. Berl. (1993) 112 (2-3):293–8.
   PubMedGoogle Scholar
• BORISON RL, ARVANITIS LA, MILLER BG: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicen-ter, placebo-controlled trial in patients with schizo-phrenia. U.S. Seroquel Study Group. J. Clin. Psychopharmacol. (1996) 16 (2):158–69.
   PubMed Web of Science ®Google Scholar
• HYTTEL J, ARNT J, COSTALL B et al: Pharmacological profile of the atypical neuroleptic setindole. Neuropharmacol (1992) 15 (Suppl. 1 Pt A):267A268A.
   Google Scholar
• PILOWSKY LS, O'CONNELL P, DAVIES N et al: In vivo occupancy of striatal dopamine D2 receptors by the novel atypical antipsychotic drug sertindole - a 1231 IBZM single positron emission tomograp hy study. Psy-chopharmacol (In Press).
   Google Scholar
• SEEGER TF, SEYMOUR PA, SCHMIDT AW eta].: Ziprasi- done (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Pharmacol Exp. Ther. (1995) 275(0:101–113.
   Google Scholar
• MELTZER HY: Role of se rotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. (1995) 3(2):64–75.
   PubMedGoogle Scholar
• KERWIN RW, TAYLOR D: New antipsychotics. A review of their current status and clinical potential. CNS Drugs(1996) 6(1):71–82. A comprehensive prescriber's guide to the atypical antipsychotics currently available.
   Google Scholar
• GOLDSTEIN JM: Pre-clinical pharmacology of new atypi-cal antipsychotics in late stage development. Exp. Opin. Invest. Drugs (1995) 4:291–298.
   Google Scholar
• CARLSON A, LINQVIST M: Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxi-col. (1963) 140–144.
   Google Scholar
• CREESE I, BURT DR, SNYDER SH: Dopamine receptor binding predicts clinical and pharmacological poten-cies of antipsychotic drugs. Science (1976) 192:481–483.
   PubMed Web of Science ®Google Scholar
• VAN TOL HH, BUNZOW JR, GUAN HC et al: Cloning of the gene for human D4 receptor with high affinity for the antipsychotic clozapine. Nature (1991) 350:610–619.
   PubMed Web of Science ®Google Scholar
• SEEMAN P, GUAN HC, VAN TOL HMM: Dopamine D4 receptors elevated in schizophrenia. Nature (1993) 365:441–445.
   PubMed Web of Science ®Google Scholar
• REYNOLDS GP, MASON S: Are striatal D4 receptors in- creased in schizophrenia? J. Neurochem. (1994) 63:1576–1577.
   PubMedGoogle Scholar
• SHAIKH S, COLLIER D, KERWIN RW et al: Dopamine D4 receptor subtypes and reponse to clozapine. Lancet (1993) 341:116.
   PubMed Web of Science ®Google Scholar
• SHAIKH S, GILL M, OWEN M et al.: Failure to find linkage between a functional polymorphism in the dopamine D4 receptor gene and schizophrenia. Am. J. Med. Gen. (Neuropsychiatric Genetics) (1994) 54:8–11.
   PubMed Web of Science ®Google Scholar
• REYNOLDS GP: The importance of dopamine D4 recep-tors in the action and development of antipsychotic agents. Drugs (1996) 51:7–11.
   PubMed Web of Science ®Google Scholar
• SHAIKH S, COLLIER DA, SHAM PC eta].: Allelic association between a ser-9-gly polymorphism in the dopamine D3 receptor gene and schizophrenia. (1996) Hum. Genet. 97: 714–719.
   Google Scholar
• RIETSCHEL M, NOETHEN MM, ALBUS M eta].: Dopamine D3 receptor gly(9)/ser(9) polymorphism and schizo-phrenia - no increased frequency of homozygosity in german familial cases. Schizophrenia Res (1996) 20:181–186.
   Google Scholar
• KAHN RS, DAVIDSON M, SIEVER L eta].: Serotonin func-tion and treatment response to clozapine in schizo-phrenic patients. Am. J. Psychiatry (1993) 150:1337–1342.
   Google Scholar
• NORDSTROM AL, FARDE L, HALLDIN C: High 5-HT2 recep-tor occupancy in clozapine-treated patients demon-strated by positron emission tomography. Psychopharmacol (1993) 110:365–367.
   PubMed Web of Science ®Google Scholar
• POMPEIANO M, PALACIOS JM, MENGOD G: Distribution of the serotonin 5-HT2 receptor family mRNAs: com-parison between 5-HT2A and 5-HT2c receptors. Mol. Brain Res. (1994) 23: 163–178.
   PubMedGoogle Scholar
• HOYER D eta].: International Union of Pharmacology classification of receptors for 5hydroxytryptamine (Se-rotonin). Pharmacol Rev. (1994) 46:157–203.
   Google Scholar
• WEINBERGER DR: Implications of Normal Brain Devel- ▪opment for the Pathogenesis of Schizophrenia. Arch. Gen. Psychiatry (1987) 44:660–669.
   PubMed Web of Science ®Google Scholar
• ASHBY CR, WANG RY: Effect of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex. Brain Res. (1990) 506:346–348.
   PubMedGoogle Scholar
• WILLIAMS J, SPURLOCK G, MCGUFFINP eta]. for the EMASS Group: Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-re-ceptor gene. Lancet (1996) 347:1294–1296.
   Google Scholar
• NIMGAONKAR VL, ZHANG XR, BEAR JS, DELEO M, GAN- GULI R: 5-11T2 receptor gene locus: association with schizophrenia or treatment response not detected. Psy-chiatric Genetics (1996) 6:23–27.
   PubMed Web of Science ®Google Scholar
• MALHOTRA AK, GOLDMAN D, BUCHANAN R, BREIER A, PICKAR D: 5-HT2A receptor T102C polymorphism and schizophrenia. Lancet (1996) 347:1830.
   Google Scholar
• ARRANZ MJ, COLLIER D, SODHI MS et al.: Association between clozapine response and allelic variation in the 5-HT2A receptor gene. Lancet (1995) 346:281–282.
   PubMed Web of Science ®Google Scholar
• NOETHEN MM, RIETSCHEL M, ERDMANN J et al.: Genetic variation of the 5-HT2A receptor and resp onse to clozap-ine. Lancet (1995) 346:908–909.
   Google Scholar
• BURNET PWJ, HARRISON PJ: Genetic variation of the5-HT2A receptor and response to clozapine. Lancet (1995) 346:909.
   Google Scholar
• MASELLIS M, PATERSON AD, BADRI F et al: Genetic variation of 5-HT2A receptor and response to clozapine. Lancet (1995) 346:1108.
   PubMed Web of Science ®Google Scholar
• MALHOTRA AK, GOLDMAN D, OZAKI N, PICKAR D: Lack of association between polymorphisms in the 5-HT2A receptor gene and antipsychotic response to clozapine. Am. J Psychiatry (1996) 150:1092–1094.
   Google Scholar
• SODH1 MS, ARRANZ MJ, CURTIS DA et al.: Associationbetween clozapine response and allelic variation in the 5-11T2c receptor gene. NeuroReport (1995) 7:369–375.
   Google Scholar
• BADRI F, MASELLIS M, PETRONIS A eta].: Dopamine and serotonin system genes may predict clinical response to clozapine. Am. J. Hum. Genet (1996) 59(4):1423.
   Google Scholar
• AUDINOT V, CANTON H, NEWMAN-TANCREDI A et al.: In vitro and ex vivo patterns of occupation of 5-HT2A and alpha-1-adrenergic as compared to dopamine D2 receptors by novel antipsychotics. Eur. Neuropsycho-pharmacol (1995) 5(3):330.
   Google Scholar
• AUDINOT V, NEWMAN-TA NCREDI A, JACQUES V, CHAPUT C, MILLAN MJ. Comparative profiles of interaction of atyical antipsychotics at cloned human hD2, hD3 and hD4 receptors: S16924 shows a marked preference for hD4 sites. Eur. Neuropsychopharmacol (1995) 5(3):330.
   Google Scholar
• KRYSTAL JH, KARPER LP, SEIBYL JP eta].: Subanaesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry (1994) 51:199–214.
   Google Scholar
• KERWIN R, PATEL S, MELDRUM BS, CZUDEK C, REYNOLDSGP: Assymmetrical loss of glutamate receptor subtypes in the left hippocampus in schizophrenia. Lancet (1988) 1:583–584.
   PubMedGoogle Scholar
• KERWIN R, PATEL S, MELDRUM BS: Quantitative autora- diographic analysis of glutamate binding sites in the hip pocampal formation in normal and schizophrenic brain post mortem. Neuroscience (1990) 39:25–32.
   PubMedGoogle Scholar
• MCLAUGHLIN DP, CHEETHAM ME, KERWIN RW: Expres-sion of alternatively-spliced glutamate receptors in hu-man hippocampus. Eur. J. Pharmacol. (Molecular Pharmacology) (1993) 89–92.
   Google Scholar
• DAS I, RAMCHAND CN, GLIDDON A et al.: Nitric oxide, free radicals and polyamines may have a role in the membrane pathology of schizophrenia. Schizophrenia Res. (1996) 18(2-3):9.
   Google Scholar
• NODA Y, YAMADA K, FURUKAWA H, NABESHIMA T: Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice. Eur. J. Pharmacol (1995) 286:291–297.
   PubMed Web of Science ®Google Scholar
• KARSON CN, GRIFFIN WST, MRAK RE et al.: Nitric oxide synthase (NOS) in schizophrenia. Increases in the cere-bellar vermis. Mol Chem. Neuropathol (1996) 27:275–284.
   PubMedGoogle Scholar
• BACHNEFF SA: Regional cerebral blood flow in schizo-phrenia and the local circuit neurons hypothesis. Schizophrenia Bull. (1996) 22(l):163–182.
   Google Scholar
• AKBARIAN S, BUNNEY WE, POTKIN SG et al.: Altered distribution of nicotinamide -ade nine dinucleotide phosphate-diaphorase cells in the frontal lobe of schizophrenics implies disturbances of cortical devel-opment. Arch. Gen. Psychiatry (1993) 50:169–177.
   PubMed Web of Science ®Google Scholar
• AKBARIAN S, VINUELA A, KIM JJ et al.: Distorted distribu-tion of nicotinamide-adenine dinucleotide phosphate - diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical develop-ment. Arch. Gen. Psychiatry (1993) 50:178–187.
   PubMed Web of Science ®Google Scholar
• MARRAS RA, MARTINS AP, DEL BEL EA, GUIMARAES FS:L-NOARG, an inhibitor ofnitric oxide synthase, induces catalepsy in mice. NeuroReport (1995) 7:158–160.
   PubMedGoogle Scholar
• DEBONNEL G, DEMONTIGNY C: Modulation of NMDA and dopaminergic neurotransmissions by sigma li-gands- possible implications for the treatment of psy-chiatric disorders. Life Sciences (1996) 58(9):721–734.
   PubMedGoogle Scholar
• MODELL S, NABER D, HOLZI3ACH R: Efficacy and safety of an opiate sigma-receptor antagonist (SL-82.0715) in schizophrenic patients with negative symptoms - an open dose range study. Pharmacopsychiatry (1996) 29(2):63–66.
   Google Scholar
• HORROBIN DF, GLEN AIM, VADDADI KS: The membrane hypothesis of schizophrenia. Schizophrenia Res. (1994) 13:195–207.
   PubMedGoogle Scholar
• HUDSON CJ, YOUNG T, LI PP, WARSH JJ: CNS signal transduction in the patlophysiology and pharma - cotherapy of affective disorders and schizophrenia. Synapse (1993) 13:278–293.
   PubMed Web of Science ®Google Scholar
• GLEN AIM, GLEN EMT, HORROBIN DF et al: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophrenia Res. (1994) 12:53–61.
   PubMedGoogle Scholar
• VAN KAMMFN D, YAO J, GOETZ K: Polyunsaturated fatty acids, prostaglandins and schizophrenia. Ann. NY Acad Sci. (1989) 559:411–423.
   PubMedGoogle Scholar
• YAO JK, VAN KAMMEN DP, VVELKER JA: Red blood cellmembrane dynamics in schizophrenia IL Fatty acid composition. Schizophrenia Res. (1994) 13:217–226.
   PubMedGoogle Scholar
• GATTAZ WF, HUBNER C, NEVALAINEN T, THUREN T, KINNUNEN PKJ: Increased serum phospholipase A2 ac-tivity in schizophrenia: a replication study. Biol. Psychia-try (1990) 28:495–501.
   PubMed Web of Science ®Google Scholar
• GATTAZ WF, KOLLISCH M, THUREN T, VIRTANEN JA, KINNUNEN PKJ: Increased plasma phospholipase A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol. Psychiatry (1987) 22:421–426.
   PubMed Web of Science ®Google Scholar
• GATTAZ WF, SCHMITT A, MARAS A: Increased plateletphospholipase A2 activity in schizophrenia. Schizophre-nia Res. (1995) 16:1–6.
   PubMed Web of Science ®Google Scholar
• HUDSON CJ, KENNEDY JL, GOTOWIEC A et al.: Genetic variant near cytosolic phospholipa se A2 associated with schizophrenia. Schizophrenia Res. (1996) 21:111–116.
   PubMedGoogle Scholar
• DUMUIS A, SEBBEN M, HAYNES L, PIN JP AND BOCKAERT J: NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature (1988) 336:68–70.
   PubMed Web of Science ®Google Scholar
• STROSZNAJDER J, SAMOCHOCKI M, DURAN M: Se rotonin, a potent modulator of arachidonic acid turnover, inter-action with glutamatergic receptor in brain cortex. Neurochem. Int (1994) 25:193–199.
   PubMedGoogle Scholar
• SHAIK S, MAKOFF AJ, COLLIER DA, KERWIN RW: Dopamine D4 receptors: potential therapeutic implica-tions in the treatment of schizophrenia. CNS Drugs (1997) (In press).
   Google Scholar